The biopharmaceutical company received $126 million in upfront cash and may also receive up to $200 million in milestone payments and royalties on net sales. It is also eligible to collect its account receivables as of the closing date, according to a statement.
Omidria is used during cataract surgery or intraocular lens replacement to help reduce postoperative ocular pain.
Price: 7.59, Change: +0.06, Percent Change: +0.80
|Evercore ISI Adjusts Apple Price Target to $180 From...|
|US Dollar Mostly Firmer Early Tuesday Ahead of Home ...|
|Graybug Vision to Conduct Review of Strategic Altern...|
|Street Color: Global Economic Data Recap|
|Guggenheim Adjusts Etsy's Price Target to $101 From ...|